Literature DB >> 17928232

Late sequelae of lobectomy for primary lung cancer: fibrobullous changes in ipsilateral residual lobes.

Hisaichi Tanaka1, Akihide Matsumura, Mitsunori Ohta, Naoki Ikeda, Naoto Kitahara, Keiji Iuchi.   

Abstract

BACKGROUND: Late complications after lobectomy for primary lung cancer are rare. Progressive fibrobullous changes in the ipsilateral residual lobes were observed in some of the long-surviving patients after lobectomy for lung cancer. We report clinical details of this late complication.
METHODS: Between 1975 and 1997, we selected 39 patients (35 males and 4 females) from a total of 1321 patients who underwent lobectomy for primary lung cancer.
RESULTS: The incidence rate of this complication was 3%; this increased to 5.6% in patients who had survived for 5 years or more. A chest roentgenogram revealed fibrobullous changes on an average of 2.5 years (range 3 months-6 years) after lobectomy; these changes progressed throughout the ipsilateral lobes over several years. Ten patients (26%) required continuous oxygen therapy. The fibrobullous lungs of 21 (54%) patients were infected with nontuberculous mycobacterium, aspergillus, methicillin-resistant Staphylococcus aureus, and unidentified bacteria in 5, 4, 1, and 11 patients, respectively. Twenty-four patients died of the following causes: cancer (8, 33%), respiratory failure and chronic infections related to this complication (10, 42%), and other diseases (6, 25%). Three patients underwent successful surgical intervention for treating chronic infection of the destroyed lungs (omentopexy 1, completion pneumonectomy 2).
CONCLUSIONS: Fibrobullous lung should be recognized as an important late complication that develops in lung cancer patients after lobectomy.

Entities:  

Mesh:

Year:  2007        PMID: 17928232     DOI: 10.1016/j.ejcts.2007.09.012

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  7 in total

Review 1.  Surgical management of non-cystic fibrosis bronchiectasis.

Authors:  Miyako Hiramatsu; Yuji Shiraishi
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

2.  Impact of lung cancer surgery on comorbid Mycobacterium avium complex lung disease-A case series.

Authors:  Atsuhisa Tamura; Masahiro Kawashima; Junko Suzuki; Akira Yamane; Yuta Inoue; Takeshi Fukami; Masashi Kitani; Fumiaki Takahashi
Journal:  Respir Med Case Rep       Date:  2022-05-04

3.  Surgical treatment for severely damaged lung and pyothorax with bronchopleural fistula 9 years after induction chemoradiotherapy and bilobectomy.

Authors:  Yoshinobu Hata; Keigo Takagi; Hidenori Goto; Hajime Otsuka
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-04-09

4.  Aspergillus Sternomyelitis Developed from Chronic Pulmonary Aspergillosis as a Late Complication to Lobectomy for Lung Cancer.

Authors:  Yuji Uehara; Hajime Kasai; Takahiro Nakajima; Nobuhiro Tanabe; Koichiro Tatsumi; Ichiro Yoshino
Journal:  Intern Med       Date:  2018-06-06       Impact factor: 1.271

5.  Incidence and Risk Factors of Chronic Pulmonary Aspergillosis Development during Long-Term Follow-Up after Lung Cancer Surgery.

Authors:  Sun Hye Shin; Bo-Guen Kim; Jiyeon Kang; Sang-Won Um; Hojoong Kim; Hong Kwan Kim; Jhingook Kim; Young Mog Shim; Yong Soo Choi; Byeong-Ho Jeong
Journal:  J Fungi (Basel)       Date:  2020-11-09

6.  Radiological unilateral pleuroparenchymal fibroelastosis as a notable late complication after lung cancer surgery: incidence and perioperative associated factors.

Authors:  Kenji Inafuku; Akimasa Sekine; Hiromasa Arai; Eri Hagiwara; Shigeru Komatsu; Tae Iwasawa; Toshihiro Misumi; Noritake Kikunishi; Michihiko Tajiri; Koji Okudela; Yasushi Rino; Takashi Ogura
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-09-09

7.  Cerebral Air Embolism and Cardiomyopathy Secondary to Large Bulla Rupture during a Pulmonary Function Test.

Authors:  Ha Lee; Hyun Soo Lee; Dulk Hwan Moon; Sungsoo Lee
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2020-02-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.